Abstract
Purpose:
Tuberous sclerosis complex is a genetic disorder characterized by the growth of hamartomas in multiple organs. Up to 80% of patients with tuberous sclerosis complex will have at least 1 angiomyolipoma in their lifetime. We describe the incidence and natural history of angiomyolipoma in a pediatric tuberous sclerosis complex population and analyze tumor growth to determine optimal renal imaging intervals in an effort to improve counseling, treatment and followup.
Materials and Methods:
We performed a retrospective chart review of all patients with tuberous sclerosis complex from 2004 to 2014. Patients were included if they had a clinical or genetic diagnosis of tuberous sclerosis complex and had undergone at least 1 renal imaging study.
Results:
A total of 145 patients were analyzed. Median age was 14 years (range 0 to 28). Overall incidence of angiomyolipoma was 50.3%. Median age at first angiomyolipoma detection was 11 years (range 2 to 26). Median yearly angiomyolipoma growth rate stratified by age at first detection was 0.0 mm for patients 0 to 6 years old, 0.9 mm for those 7 to 11 years old, 2.5 mm for those 12 to 16 years old and 1.8 mm for those 17 years old or older. Median yearly angiomyolipoma growth rate stratified by tumor size at first detection was 0.1 mm for tumors 0.6 to 0.9 cm, 1.8 mm for those 1.0 to 1.9 cm and 4.3 mm for those 2.0 to 2.9 cm. A total of 35 patients (24.1%) received mTOR (mammalian target of rapamycin) inhibitors. Eight patients underwent a total of 13 surgical interventions, of whom 2 had previously been treated with mTOR inhibitors. Median patient age at surgical intervention was 18.0 years and median angiomyolipoma size was 5.0 cm.
Conclusions:
Angiomyolipoma growth in children with tuberous sclerosis complex can be rapid and unpredictable. We recommend yearly renal ultrasound in all patients with tuberous sclerosis complex, with consideration of magnetic resonance imaging in those at risk for rapid growth and future intervention (ie those older than 11 years and/or those with renal angiomyolipomas larger than 2 cm).
References
- 1 : The tuberous sclerosis complex. N Engl J Med2006; 355: 1345. Google Scholar
- 2 : Tuberous sclerosis. Lancet2008; 372: 657. Google Scholar
- 3 : Causes of death in patients with tuberous sclerosis. Mayo Clin Proc1991; 66: 792. Google Scholar
- 4 :
Pediatric urologic oncology . In: Campbell-Walsh Urology. Edited by . Philadelphia: Elsevier Saunders2012. vol 4, chapt 137, pp 3724–3725. Google Scholar - 5 : Renal lesion growth in children with tuberous sclerosis complex. J Urol1998; 160: 141. Link, Google Scholar
- 6 : Angiomyolipoma: clinical metamorphosis and concepts for management. J Urol1988; 139: 20. Link, Google Scholar
- 7 : Renal angiomyolipoma: optimal treatment based on size and symptoms. Clin Nephrol1998; 49: 281. Google Scholar
- 8 : The natural history of renal angiomyolipoma. J Urol1993; 150: 1782. Link, Google Scholar
- 9 : Embolization of renal angiomyolipomata in patients with tuberous sclerosis complex. Am J Kidney Dis2006; 47: 95. Google Scholar
- 10 : Urological counseling and followup in pediatric tuberous sclerosis complex. J Urol2007; 178: 2155. Link, Google Scholar
- 11 : Association between the growth rate of renal cysts/angiomyolipomas and age in the patients with tuberous sclerosis complex. Int Urol Nephrol2014; 46: 1685. Google Scholar
- 12 : A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr1985; 106: 522. Google Scholar
- 13 : Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors. Kidney Int2006; 70: 1777. Google Scholar
- 14 : Tuberous sclerosis complex: renal imaging findings. Radiology2002; 225: 451. Google Scholar
- 15 : The radiological diagnosis and treatment of renal angiomyolipoma—current status. Clin Radiol2010; 65: 99. Google Scholar
- 16 : Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol2013; 49: 255. Google Scholar
- 17 : The tuberous sclerosis complex and its highly variable manifestations. J Urol2003; 169: 1635. Link, Google Scholar
- 18 : Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet2013; 381: 817. Google Scholar
- 19 : Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet2001; 68: 64. Google Scholar
- 20 : Comprehensive mutation analysis of TSC1 and TSC2—and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet1999; 64: 1305. Google Scholar
- 21 : Facilitated diagnosis of the contiguous gene syndrome: tuberous sclerosis and polycystic kidneys by means of haplotype studies. Am J Kidney Dis1998; 31: 1038. Google Scholar
- 22 : Tuberous sclerosis complex renal disease. Nephron Exp Nephrol2011; 118: e15. Google Scholar
- 23 : The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, phase 3 trial EXIST-1. Nephrol Dial Transplant2014; 29: 1203. Google Scholar
